FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC By Ogkologos - June 24, 2026 184 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast02 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR New hormone treatment for advanced prostate cancer made available in England June 8, 2021 Children’s Hospital Lets Kids Ride Toy Cars Into Surgery To Ease... June 19, 2019 El cáncer en mi comunidad: El rol de la detección del... November 5, 2020 Using Aspirin to Prevent Breast Cancer Recurrence and Targeted Therapy for... February 14, 2022 Load more HOT NEWS Picking out the patterns: How scientists are finding cancer’s signatures in... Online Dating During COVID-19 and Cancer: What to Know Modest Population-Level Increases in Survival Observed After Implementation of Immune Checkpoint... Adagrasib Shows Clinical Efficacy in Patients with Previously Treated KRASG12C-Mutated Advanced...
